Patents by Inventor John Tyhonas

John Tyhonas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
    Publication number: 20230374015
    Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: June 4, 2021
    Publication date: November 23, 2023
    Inventors: Stephen W. KALDOR, John TYHONAS, Eric A. MURPHY, Toufike KANOUNI, Lee D. ARNOLD, Robert KANIA
  • Inhibtors of Raf kinases
    Patent number: 11814384
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: November 14, 2023
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Jason M. Cox, John Tyhonas, Robert S. Kania, Subhas J. Chakravorty, Young K. Chen
  • INHIBITORS OF RAF KINASES
    Publication number: 20230303566
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: February 3, 2023
    Publication date: September 28, 2023
    Inventors: Toufike KANOUNI, Jason M. COX, John TYHONAS, Robert S. KANIA, Subhas J. CHAKRAVORTY, Young K. CHEN
  • INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
    Publication number: 20230174535
    Abstract: Provided herein are inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: May 14, 2020
    Publication date: June 8, 2023
    Inventors: Stephen W. KALDOR, John TYHONAS
  • INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
    Publication number: 20230078839
    Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: March 23, 2022
    Publication date: March 16, 2023
    Inventors: Stephen W. KALDOR, John TYHONAS, Eric A. MURPHY, Toufike KANOUNI, Lee D. ARNOLD, Robert KANIA, Jason M. COX
  • INHIBITORS OF RAF KINASES
    Publication number: 20230081390
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: March 20, 2020
    Publication date: March 16, 2023
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, Eric A. MURPHY, Lee D. ARNOLD, John TYHONAS
  • TREATMENT OF CANCER WITH CDK12/13 INHIBITORS
    Publication number: 20230074545
    Abstract: Provided herein are compositions and methods for the treatment of a triple-negative breast cancer, ovarian cancer and castration-resistant prostate cancer. Said compositions comprise CDK12/13 inhibitors.
    Type: Application
    Filed: December 23, 2020
    Publication date: March 9, 2023
    Inventors: Eric A. MURPHY, John TYHONAS, Noelito TIMPLE, Toufike KANOUNI, Lee D. ARNOLD, Elisabeth GARDINER, Eric MARTIN
  • INHIBITORS OF CYCLIN-DEPENDENT KINASES
    Publication number: 20220388990
    Abstract: Provided herein are compounds which are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: July 16, 2020
    Publication date: December 8, 2022
    Inventors: Toufike KANOUNI, Lee D. ARNOLD, Stephen W. KALDOR, Eric A. MURPHY, John TYHONAS
  • INHIBITORS OF RAF KINASES
    Publication number: 20220340543
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: April 26, 2022
    Publication date: October 27, 2022
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, John TYHONAS, Eric MURPHY, Jason COX, Robert KANIA
  • Inhibitors of RAF kinases
    Patent number: 11407737
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: September 16, 2021
    Date of Patent: August 9, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, Toufike Kanouni, John Tyhonas, Eric Murphy, Jason Cox, Robert Kania
  • Inhibitors of cyclin-dependent kinases
    Patent number: 11390618
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: July 19, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Lee D. Arnold, Stephen W. Kaldor, Eric A. Murphy, John Tyhonas
  • Inhibitors of cyclin-dependent kinases
    Patent number: 11358958
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: June 14, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Lee D. Arnold, Stephen W. Kaldor, Eric A. Murphy, John Tyhonas
  • Inhibitors of fibroblast growth factor receptor kinases
    Patent number: 11345681
    Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: May 31, 2022
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, John Tyhonas, Eric A. Murphy, Toufike Kanouni, Lee D. Arnold, Robert Kania, Jason M. Cox
  • INHIBITORS OF RAF KINASES
    Publication number: 20220089569
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: September 16, 2021
    Publication date: March 24, 2022
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, John TYHONAS, Eric MURPHY, Jason COX, Robert KANIA
  • Substituted amines for treating cardiac diseases
    Patent number: 11197858
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: December 14, 2021
    Assignee: Cardurion Pharmaceuticals, LLC
    Inventors: Nobuyuki Matsunaga, Takashi Nakahata, Yuta Tanaka, Hiroki Takahagi, Yasufumi Miyamoto, Rei Okamoto, Takeshi Yoshikawa, Yoshito Terao, Takafumi Yukawa, Keiko Kakegawa, Yoichi Nishikawa, Terufumi Takagi, Masashi Takahashi, Mallareddy Komandla, Lily Kwok, Joanne Miura, Mark Sabat, Nicholas Scorah, Paul Tanis, John Tyhonas, Phong H. Vu, Haixia Wang, Xiaolun Wang, Junya Shirai, Tomohiro Okawa, Zenyu Shiokawa, Akito Shibuya
  • INHIBITORS OF RAF KINASES
    Publication number: 20210300904
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: March 25, 2021
    Publication date: September 30, 2021
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, John TYHONAS, Eric MURPHY
  • Inhibitors of RAF kinases
    Patent number: 11098031
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: August 24, 2021
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, Toufike Kanouni, John Tyhonas, Eric Murphy
  • INHIBITORS OF CYCLIN-DEPENDENT KINASES
    Publication number: 20210130340
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: November 11, 2020
    Publication date: May 6, 2021
    Inventors: Toufike KANOUNI, Lee D. ARNOLD, Stephen W. KALDOR, Eric A. MURPHY, John TYHONAS
  • Inhibitors of cyclin-dependent kinases
    Patent number: 10894788
    Abstract: Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: January 19, 2021
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Toufike Kanouni, Lee D. Arnold, Stephen W. Kaldor, Eric A. Murphy, John Tyhonas
  • SUBSTITUTED AMINES FOR TREATING CARDIAC DISEASES
    Publication number: 20200230137
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: January 27, 2020
    Publication date: July 23, 2020
    Applicant: Cardurion Pharmaceuticals, LLC
    Inventors: Nobuyuki MATSUNAGA, Takashi NAKAHATA, Yuta TANAKA, Hiroki TAKAHAGI, Yasufumi MIYAMOTO, Rei OKAMOTO, Takeshi YOSHIKAWA, Yoshito TERAO, Takafumi YUKAWA, Keiko KAKEGAWA, Yoichi NISHIKAWA, Terufumi TAKAGI, Masashi TAKAHASHI, Mallareddy KOMANDLA, Lily KWOK, Joanne MIURA, Mark SABAT, Nicholas SCORAH, Paul TANIS, John TYHONAS, Phong H. VU, Haixia WANG, Xiaolun WANG, Junya SHIRAI, Tomohiro OKAWA, Zenyu SHIOKAWA, Akito SHIBUYA